IDEXX LABORATORIES INC /DE Contract Liability (Deferred Revenue)
IDEXX LABORATORIES INC /DE (IDXX) had Contract Liability (Deferred Revenue) of $36.40 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Contract with Customer, Liability, Current $36.40M.
- 2026-03-31: Contract with Customer, Liability, Current $36.33M.
- 2025-12-31: Contract with Customer, Liability, Current $35.26M.
- 2025-09-30: Contract with Customer, Liability, Current $35.69M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $36.40M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $36.33M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $35.26M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $35.69M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $36.32M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $35.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $33.80M 10-K · filed 2026-02-20 |
| 2024-09-30 | $38.43M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $38.00M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $38.19M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $37.20M 10-K · filed 2025-02-21 |
| 2023-09-30 | $37.28M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $37.78M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $37.84M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $37.94M 10-K · filed 2024-02-22 |
| 2022-09-30 | $40.81M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $40.77M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $40.91M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $40.03M 10-K · filed 2023-02-16 |
| 2021-09-30 | $41.13M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $41.13M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $41.64M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $42.57M 10-K · filed 2022-02-16 |
| 2020-09-30 | $42.60M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $36.32M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $38.03M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $41.46M 10-K · filed 2021-02-12 |
| 2019-09-30 | $42.99M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $43.45M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $43.35M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $41.29M 10-K · filed 2020-02-14 |
| 2018-09-30 | $41.15M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $29.18M 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |